Regulatory press release2024-01-29 11:26Completion of the combination between Novozymes and Chr. Hansen
Regulatory press release2024-01-26 12:09All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
Press release2023-12-20 15:02Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
Regulatory press release2023-12-19 11:54Major shareholder announcement from Burlington Loan Management DAC
Press release2023-12-12 17:11Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
Regulatory press release2023-11-20 08:03Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
Regulatory press release2023-10-10 08:08Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
Regulatory press release2023-09-27 09:23Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP
Regulatory press release2023-09-04 11:48Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
Regulatory press release2023-03-30 18:07Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
Regulatory press release2023-03-30 17:57Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S
Regulatory press release2023-03-30 13:11Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
Regulatory press release2023-03-28 12:07Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
Regulatory press release2023-03-08 08:00Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company